Zomedica Pharmaceuticals Overview
- Status
-
Public
- Employees
-
141
- Stock Symbol
-
ZOMDF
- Investments
-
7
- Share Price
-
$0.08
- (As of Friday Closing)
Zomedica Pharmaceuticals General Information
Description
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.
Contact Information
Website
www.zomedica.comCorporate Office
- 100 Phoenix Drive
- Suite 190
- Ann Arbor, MI 48108
- United States
Corporate Office
- 100 Phoenix Drive
- Suite 190
- Ann Arbor, MI 48108
- United States
Zomedica Pharmaceuticals Stock Performance
As of 20-Nov-2026, Zomedica Pharmaceuticals’s stock price is $0.08. Its current market cap is $78.5M with 980M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.08 | $0.08 | $0.07 - $0.16 | $78.5M | 980M | 947K | -$0.01 |
Zomedica Pharmaceuticals Financials Summary
As of 30-Sep-2026, Zomedica Pharmaceuticals has a trailing 12-month revenue of $38.7M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 36,093 | 48,939 | 42,796 | 91,731 |
| Revenue | 38,681 | 32,030 | 27,285 | 25,186 |
| EBITDA | (10,413) | (76,620) | (43,519) | (34,845) |
| Net Income | (15,995) | (81,858) | (46,982) | (34,529) |
| Total Assets | 115,026 | 127,039 | 207,360 | 253,197 |
| Total Debt | 1,648 | 2,184 | 1,814 | 2,730 |
Zomedica Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zomedica Pharmaceuticals Comparisons
Industry
Financing
Details
Zomedica Pharmaceuticals Competitors (4)
One of Zomedica Pharmaceuticals’s 4 competitors is Grifols Diagnostic Solutions, a Corporate Backed or Acquired company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Grifols Diagnostic Solutions | Corporate Backed or Acquired | Emeryville, CA | ||||
| Idexx Laboratories | Formerly VC-backed | Westbrook, ME | ||||
| Ocugen | Formerly VC-backed | Malvern, PA | ||||
| Antech Diagnostics | Corporation | Fountain Valley, CA |
Zomedica Pharmaceuticals Patents
Zomedica Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210024644-A1 | N-cadherin binding molecules and uses thereof | Inactive | 25-Jul-2019 | ||
| WO-2021016552-A1 | N-cadherin binding molecules and uses thereof | Inactive | 25-Jul-2019 | ||
| WO-2021007007-A1 | Compositions and methods for diagnosing urinary tract infections | Inactive | 05-Jul-2019 | ||
| US-20200172979-A1 | Compositions and methods for identifying cancer | Inactive | 04-Dec-2018 | ||
| WO-2020117809-A1 | Compositions and methods for identifying cancer | Inactive | 04-Dec-2018 | G16B20/10 |
Zomedica Pharmaceuticals Signals
Zomedica Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Zomedica Pharmaceuticals Investments & Acquisitions (7)
Zomedica Pharmaceuticals’s most recent deal was a Merger/Acquisition with Qorvo Biotechnologies for . The deal was made on 05-Oct-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Qorvo Biotechnologies | 05-Oct-2023 | Merger/Acquisition | Diagnostic Equipment | ||
| Structured Monitoring Products | 05-Sep-2023 | Merger/Acquisition | Monitoring Equipment | ||
| Assisi Animal Health | 15-Jul-2022 | Merger/Acquisition | Other Consumer Durables | ||
| Revo Squared | 01-Jul-2022 | Merger/Acquisition | Business/Productivity Software | ||
| Structured Monitoring Products | 19-May-2022 | Secondary Transaction - Private | Monitoring Equipment |
Zomedica Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
Zomedica Pharmaceuticals Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Assisi Animal Health | New Vernon, NJ | 2010 | |
| PulseVet Technologies | Roswell, GA | 2009 |
Zomedica Pharmaceuticals FAQs
-
Where is Zomedica Pharmaceuticals headquartered?
Zomedica Pharmaceuticals is headquartered in Ann Arbor, MI.
-
What is the size of Zomedica Pharmaceuticals?
Zomedica Pharmaceuticals has 141 total employees.
-
What industry is Zomedica Pharmaceuticals in?
Zomedica Pharmaceuticals’s primary industry is Other Healthcare Services.
-
Is Zomedica Pharmaceuticals a private or public company?
Zomedica Pharmaceuticals is a Public company.
-
What is Zomedica Pharmaceuticals’s stock symbol?
The ticker symbol for Zomedica Pharmaceuticals is ZOMDF.
-
What is the current stock price of Zomedica Pharmaceuticals?
As of 20-Nov-2026 the stock price of Zomedica Pharmaceuticals is $0.08.
-
What is the current market cap of Zomedica Pharmaceuticals?
The current market capitalization of Zomedica Pharmaceuticals is $78.5M.
-
What is Zomedica Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Zomedica Pharmaceuticals is $38.7M.
-
Who are Zomedica Pharmaceuticals’s competitors?
Grifols Diagnostic Solutions, Idexx Laboratories, Ocugen, and Antech Diagnostics are competitors of Zomedica Pharmaceuticals.
-
What is Zomedica Pharmaceuticals’s annual earnings per share (EPS)?
Zomedica Pharmaceuticals’s EPS for 12 months was -$0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process